Biogen Inc (NASDAQ:BIIB) reported better-than-expected fourth-quarter results, prompting analysts to share insights on the company’s trajectory.
- Wedbush analyst Laura Chico maintained a Neutral rating, while lifting the price target from $178 to $187.
- HC Wainwright analyst Andrew Fein reiterated a Buy rating and raised the price target from $194 to $228.
Check out other analyst stock ratings.
Wedbush: Biogen reported its quarterly revenues and earnings ahead of expectations for both the fourth quarter and the full year 2025, Chico said in a note. Although the management team did a commendable job in realigning the cost base, revenue growth drivers remain “the critical missing piece for the turnaround story,” she added.
While newer products (Leqembi, Skyclarys, Zurzuvae, Qalsody) generated around $980 million in sales in 2025, management expects …